Company intelligence / Profile preview

QuadMedicine

Seongnam, Gyeonggi-do, South Koreaquadmedicine.com ↗

Ownership: Private
Development stage: Other

Overview

QuadMedicine has demonstrated that its microneedle patches can deliver vaccines and allergens effectively into the skin with minimal pain. Preclinical studies show precise dosing and effective immunization in animal models. The company is developing multi-vaccine patches for use in low-resource settings with support from global health organizations. No late-stage or commercialized products are reported as of June 2025.

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Microneedle array patch (MAP)VaccineDNA vaccineSmall molecule (potential, based on drug delivery platform)
Industry: Biotech

Drug pipeline

1 asset

QMV-24KRP

Partnerships

International Vaccine Institute (IVI)LG Chem

Beyond the preview

Go deeper on QuadMedicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QuadMedicine.

Explore the full profile